2. Academic Wits University Research Outputs (All submissions)
Permanent URI for this communityhttps://hdl.handle.net/10539/36826
Browse
Search Results
Item Autoantibodies to ADAMST13 in human immunodeficiency virusassociated thrombotic thrombocytopenic purpura(WILEY-BLACKWELL) M Meiring; Mmakgabu Khemisi; Susan Louw; Palanisamy KrisnanItem Thrombosis AETiology of Aviation-Related Travel: The THETA O Study(WILEY-BLACKWELL) Barry Jacobson; Susan Louw; Elise Schapkaitz; Fatima LaherItem Verification of a Benchtop Haematology Analyzer with a 5 differential Count There is nothing wrong with being small(WILEY-BLACKWELL) Anima Baiden; Elise Schapkaitz; Maynolia Naidoo; Susan LouwItem Selected inflammatory and coagulation biomarkers previral suppression in people with human immunodeficiency virus HIV infection without overt cardiovascular disease Is there a need to redefine reference indices(ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD) Susan Louw; E Mayne; Barry Jacobson; Anthony MayneItem A case series of factor v leiden mutation in pregnancyJenique Bailly; Barry Jacobson; Susan LouwItem Verification of the qLabs international normalized ratio pointofcare device for monitoring of patients attending an anticoagulation clinicConstance Mbokota; Elise Schapkaitz; Susan LouwItem The Novel Coronavirus and Haemostatic abnormalities pathophysiology clinical manifesttations and treatment recommendationsSusan Louw; Barry Jacobson; Elizabeth Mayne; Tracey WiggillThe COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated.